Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice
The review presents an analysis of studies on the role of armolipid in the primary prevention of cardiovascular diseases. Armolipid is the nutraceutical that combines the lipid-lowering components of red yeast rice (monocalin K, policosanol) and antioxidants (coenzyme Q, astaxanthin and folic acid)....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2019-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2440 |
| _version_ | 1797882385660903424 |
|---|---|
| author | O. Sh. Oinotkinova E. L. Nikonov E. V. Kryukov A. P. Baranov M. I. Voevoda |
| author_facet | O. Sh. Oinotkinova E. L. Nikonov E. V. Kryukov A. P. Baranov M. I. Voevoda |
| author_sort | O. Sh. Oinotkinova |
| collection | DOAJ |
| description | The review presents an analysis of studies on the role of armolipid in the primary prevention of cardiovascular diseases. Armolipid is the nutraceutical that combines the lipid-lowering components of red yeast rice (monocalin K, policosanol) and antioxidants (coenzyme Q, astaxanthin and folic acid). The multifactorial evolution of atherosclerotic plaque with dyslipidemia, inflammation and genetic markers and practicability of primary prevention is shown. The presented data demonstrated that the intake of nutraceuticals is well tolerated. It also reduces the levels of total cholesterol, low-density lipoprotein cholesterol and inflammatory markers and improves vascular endothelial function. Nutraceuticals with lipid-lowering effects can be used as an alternative method of primary prevention in people with low and borderline cardiovascular risk before statin therapy, with poor adherence to statin therapy, as well as with statin intolerance or side effects. |
| first_indexed | 2024-04-10T03:34:57Z |
| format | Article |
| id | doaj.art-446a592866624b3d8b95ac0be175b1e7 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:34:57Z |
| publishDate | 2019-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-446a592866624b3d8b95ac0be175b1e72023-03-13T07:23:28Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252019-12-01186889810.15829/1728-8800-2019-6-88-982028Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast riceO. Sh. Oinotkinova0E. L. Nikonov1E. V. Kryukov2A. P. Baranov3M. I. Voevoda4Московский государственный университет им. М. В. Ломоносова; Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города МосквыРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава РоссииГлавный военный клинический госпиталь им. Н.Н. Бурденко Минобороны РоссииМосковский государственный университет им. М. В. Ломоносова; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава РоссииФедеральный исследовательский центр фундаментальной и трансляционной медициныThe review presents an analysis of studies on the role of armolipid in the primary prevention of cardiovascular diseases. Armolipid is the nutraceutical that combines the lipid-lowering components of red yeast rice (monocalin K, policosanol) and antioxidants (coenzyme Q, astaxanthin and folic acid). The multifactorial evolution of atherosclerotic plaque with dyslipidemia, inflammation and genetic markers and practicability of primary prevention is shown. The presented data demonstrated that the intake of nutraceuticals is well tolerated. It also reduces the levels of total cholesterol, low-density lipoprotein cholesterol and inflammatory markers and improves vascular endothelial function. Nutraceuticals with lipid-lowering effects can be used as an alternative method of primary prevention in people with low and borderline cardiovascular risk before statin therapy, with poor adherence to statin therapy, as well as with statin intolerance or side effects.https://cardiovascular.elpub.ru/jour/article/view/2440дислипидемияпервичная профилактиканутрицевтиккрасный дрожжевой рисармолипид |
| spellingShingle | O. Sh. Oinotkinova E. L. Nikonov E. V. Kryukov A. P. Baranov M. I. Voevoda Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice Кардиоваскулярная терапия и профилактика дислипидемия первичная профилактика нутрицевтик красный дрожжевой рис армолипид |
| title | Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice |
| title_full | Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice |
| title_fullStr | Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice |
| title_full_unstemmed | Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice |
| title_short | Evolution of dyslipidemia: from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice |
| title_sort | evolution of dyslipidemia from etiological mechanisms to new targets of personalized preventive nutraceutical therapy with red yeast rice |
| topic | дислипидемия первичная профилактика нутрицевтик красный дрожжевой рис армолипид |
| url | https://cardiovascular.elpub.ru/jour/article/view/2440 |
| work_keys_str_mv | AT oshoinotkinova evolutionofdyslipidemiafrometiologicalmechanismstonewtargetsofpersonalizedpreventivenutraceuticaltherapywithredyeastrice AT elnikonov evolutionofdyslipidemiafrometiologicalmechanismstonewtargetsofpersonalizedpreventivenutraceuticaltherapywithredyeastrice AT evkryukov evolutionofdyslipidemiafrometiologicalmechanismstonewtargetsofpersonalizedpreventivenutraceuticaltherapywithredyeastrice AT apbaranov evolutionofdyslipidemiafrometiologicalmechanismstonewtargetsofpersonalizedpreventivenutraceuticaltherapywithredyeastrice AT mivoevoda evolutionofdyslipidemiafrometiologicalmechanismstonewtargetsofpersonalizedpreventivenutraceuticaltherapywithredyeastrice |